Pyxis Oncology Inc (PYXS)

2026-09-09T15:05:21.000Z - 18 hours ago

Pyxis Oncology price target raised to $19 from $12 at Wells Fargo

2026-09-09T11:41:58.000Z - 22 hours ago

Pyxis Oncology announces updated results from micvotabart pelidotin study

Sep 9, 2026, 7:30 AM EDT - 22 hours ago

Pyxis Oncology Transcript: Study update

Sep 9, 2026, 7:30 AM EDT - 22 hours ago

Pyxis Oncology Press release: Study update

Sep 9, 2026, 7:30 AM EDT - 22 hours ago

Pyxis Oncology Slides: Study update

Sep 9, 2026, 7:00 AM EDT - 23 hours ago

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Sep 8, 2026, 4:01 PM EDT - 1 day ago

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

2026-09-08T11:50:16.000Z - 1 day ago

Pyxis Oncology appoints Thomas Civik as CEO, chairman

Sep 8, 2026, 7:30 AM EDT - 1 day ago

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

Sep 1, 2026, 7:30 AM EDT - 8 days ago

Pyxis Oncology to Participate in Upcoming Investor Conferences

2026-08-20T20:30:12.000Z - 20 days ago

Pyxis Oncology files to sell 39.2M shares of common stock for holders

Aug 20, 2026, 8:00 AM EDT - 20 days ago

Pyxis Oncology Registration statement: Registration filing

2026-08-17T08:10:42.000Z - 24 days ago

Pyxis Oncology reports Q2 EPS (40c), consensus (35c)

Aug 13, 2026, 8:00 AM EDT - 27 days ago

Pyxis Oncology Slides: Corporate presentation

Aug 13, 2026, 7:00 AM EDT - 27 days ago

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Aug 13, 2026, 7:00 AM EDT - 27 days ago

Pyxis Oncology Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 27 days ago

Pyxis Oncology Earnings release: Q2 2026

2026-08-03T09:10:27.000Z - 5 weeks ago

Pyxis Oncology initiated with an Overweight at Wells Fargo

2026-06-30T11:50:10.000Z - 2 months ago

Pyxis Oncology announces up to $114M private placement

Jun 30, 2026, 7:30 AM EDT - 2 months ago

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Jun 4, 2026, 7:35 AM EDT - 3 months ago

Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2026

May 20, 2026, 3:30 PM EDT - 3 months ago

Pyxis Oncology Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 19, 2026, 2:35 PM EDT - 3 months ago

Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-14T13:11:04.000Z - 3 months ago

Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)

May 14, 2026, 7:00 AM EDT - 3 months ago

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

May 14, 2026, 7:00 AM EDT - 3 months ago

Pyxis Oncology Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Pyxis Oncology Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Pyxis Oncology Slides: Investor presentation

May 7, 2026, 4:05 PM EDT - 4 months ago

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

2026-05-05T11:59:21.000Z - 4 months ago

Wedbush bullish on Pyxis Oncology, initiates with an Outperform

2026-05-05T11:30:55.000Z - 4 months ago

Pyxis Oncology initiated with an Outperform at Wedbush

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Pyxis Oncology Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Pyxis Oncology Proxy statement: Proxy filing

Apr 17, 2026, 4:05 PM EDT - 4 months ago

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

2026-03-24T10:51:42.000Z - 5 months ago

Pyxis Oncology price target lowered to $8 from $9 at Stifel

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Pyxis Oncology Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Pyxis Oncology Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Pyxis Oncology Slides: Corporate presentation

2026-02-03T12:00:53.000Z - 7 months ago

Pyxis Oncology appoints board member Thomas Civik as Interim CEO

Feb 3, 2026, 6:45 AM EST - 7 months ago

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

2025-12-19T14:30:40.000Z - 8 months ago

Pyxis Oncology price target lowered to $5 from $8 at RBC Capital

2025-12-19T11:15:22.000Z - 8 months ago

Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright

Dec 18, 2025, 8:30 AM EST - 8 months ago

Pyxis Oncology Transcript: Study Update

Dec 18, 2025, 8:30 AM EST - 8 months ago

Pyxis Oncology Press release: Study Update

Dec 18, 2025, 8:30 AM EST - 8 months ago

Pyxis Oncology Slides: Study Update

2025-12-18T12:18:15.000Z - 8 months ago

Pyxis Oncology announces preliminary Phase 1 data for micvotabart pelidotin

MRK

2025-12-18T12:17:56.000Z - 8 months ago

Pyxis to present updated data from Phase 1 monotherapy study in mid-2026

2025-12-18T12:17:22.000Z - 8 months ago

Pyxis Oncology sees cash runway into 4Q26

Dec 18, 2025, 7:00 AM EST - 8 months ago

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

2025-11-26T14:15:39.000Z - 9 months ago

Pyxis Oncology files $350M mixed securities shelf

Nov 26, 2025, 7:00 AM EST - 9 months ago

Pyxis Oncology Registration statement: Registration Filing

2025-11-24T12:35:39.000Z - 9 months ago

Pyxis Oncology price target raised to $8 from $5 at Stephens

Nov 11, 2025, 4:00 PM EST - 10 months ago

Pyxis Oncology Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 2:30 PM EST - 10 months ago

Pyxis Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 4:00 PM EST - 10 months ago

Pyxis Oncology Quarterly report: Q3 2025

Nov 3, 2025, 7:00 AM EST - 10 months ago

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 13, 2025, 4:05 PM EDT - 11 months ago

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Oct 9, 2025, 7:30 AM EDT - 11 months ago

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

Sep 30, 2025, 4:24 PM EDT - 11 months ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 10:30 AM EDT - 1 year ago

Pyxis Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 2:45 PM EDT - 1 year ago

Pyxis Oncology Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in September Investor and Industry Conferences

Aug 14, 2025, 4:05 PM EDT - 1 year ago

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Quarterly report: Q2 2025

Jun 5, 2025, 4:55 PM EDT - 1 year ago

Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2025

May 21, 2025, 2:05 PM EDT - 1 year ago

Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 16, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Slides: Corporate Presentation

May 15, 2025, 7:00 AM EDT - 1 year ago

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 6:00 PM EDT - 1 year ago

Pyxis Oncology Earnings release: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Pyxis Oncology Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing

Apr 25, 2025, 1:17 PM EDT - 1 year ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Apr 9, 2025, 11:30 AM EDT - 1 year ago

Pyxis Oncology Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Pyxis Oncology Earnings release: Q4 2024

Mar 18, 2025, 7:30 AM EDT - 1 year ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 2:20 PM EDT - 1 year ago

Pyxis Oncology Transcript: Leerink Global Healthcare Conference 2025

Mar 3, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Feb 4, 2025, 7:30 AM EST - 1 year ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Dec 19, 2024, 4:08 PM EST - 1 year ago

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Nov 20, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology Transcript: Status Update

Nov 20, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology Slides: Status Update

Nov 20, 2024, 4:05 PM EST - 1 year ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Nov 18, 2024, 7:00 AM EST - 1 year ago

Pyxis Oncology Quarterly report: Q3 2024

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Proxy statement: Proxy Filing

Sep 9, 2024, 2:00 PM EDT - 2 years ago

Pyxis Oncology Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 12:20 PM EDT - 2 years ago

Pyxis Oncology Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14, 2024, 4:05 PM EDT - 2 years ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Slides: Q2 2024

Jul 29, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Jun 10, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

May 30, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 14, 2024, 4:00 PM EDT - 2 years ago

Pyxis Oncology Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Pyxis Oncology Earnings release: Q1 2024

May 14, 2024, 3:05 PM EDT - 2 years ago

Pyxis Oncology Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

May 9, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Proxy statement: Proxy Filing

Apr 16, 2024, 1:30 PM EDT - 2 years ago

Pyxis Oncology Transcript: Stifel Virtual Targeted Oncology Days Conference

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Registration statement: Registration Filing

Mar 27, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Mar 21, 2024, 7:30 AM EDT - 2 years ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pyxis Oncology Annual report: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pyxis Oncology Earnings release: Q4 2023

Mar 13, 2024, 8:40 AM EDT - 2 years ago

Pyxis Oncology Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Mar 7, 2024, 4:30 PM EST - 2 years ago

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Mar 5, 2024, 4:45 PM EST - 2 years ago

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Dec 19, 2023, 12:50 PM EST - 2 years ago

Pyxis Oncology Slides: Corporate Presentation

Nov 7, 2023, 4:30 PM EST - 2 years ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Nov 7, 2023, 7:00 AM EST - 2 years ago

Pyxis Oncology Quarterly report: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Pyxis Oncology Earnings release: Q3 2023

Sep 27, 2023, 9:18 AM EDT - 2 years ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Aug 31, 2023, 4:01 PM EDT - 3 years ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Aug 23, 2023, 8:35 AM EDT - 3 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Pyxis Oncology Earnings release: Q2 2023

Aug 10, 2023, 2:56 PM EDT - 3 years ago

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Aug 1, 2023, 4:01 PM EDT - 3 years ago

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Jul 10, 2023, 3:01 AM EDT - 3 years ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan